Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

39.82
+0.24500.62%
Volume:4.84M
Turnover:193.82M
Market Cap:28.76B
PE:-84.71
High:40.97
Open:40.45
Low:39.50
Close:39.57
52wk High:42.50
52wk Low:14.50
Shares:722.41M
Float Shares:581.00M
Volume Ratio:0.77
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:6.80
PE(LYR):-73.73

Loading ...

BUZZ-Roivant rises as arthritis drug shows early promise

Reuters
·
May 20

Movement Alert|Roivant Sciences Rises 11.1% in Regular Trading, Business Progress Updates Drive Positive Market Reaction Despite Revenue Miss

Market Focus
·
May 20

Roivant Sciences Ltd reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 20

Immunovant Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 20

Movement Alert|Roivant Sciences Rises 8.12% in Pre-Market Trading, Reports Fiscal Q4 Results and Business Updates

Market Focus
·
May 20

S&P 500 Futures Rise In Premarket Trading; Immunovant, ImmunityBio Lead

Dow Jones
·
May 20

Roivant Sciences Swings to Fiscal Q4 Net Income, Revenue Decreases

MT Newswires Live
·
May 20

Stock Track | Roivant Sciences Soars 9.89% in Pre-Market on Unexpected Q4 Profit from Moderna Lawsuit Settlement

Stock Track
·
May 20

Immunovant Inc Q4 net loss misses on higher R&D costs

Reuters
·
May 20

Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain

Reuters
·
May 20

Earnings Flash (ROIV) Roivant Posts Fiscal Q4 EPS From Continuing Operations $0.28

MT Newswires Live
·
May 20

Roivant Q4 swings to profit of $355.7 million; revenue falls to $2.52 million

Reuters
·
May 20

Roivant Sciences Q4 Sales $2.520M Miss $3.820M Estimate

Benzinga Earnings
·
May 20

BRIEF-Roivant Sciences Q4 Revenue USD 2.52 Million

Reuters
·
May 20

Immunovant Q4 net loss widens to $147.86 million

Reuters
·
May 20

Roivant Sciences Q4 Operating Expenses USD 357.515 Million

THOMSON REUTERS
·
May 20

Roivant Sciences Q4 EPS USD 0.28

THOMSON REUTERS
·
May 20

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

THOMSON REUTERS
·
May 20

A Look At Roivant Sciences (ROIV) Valuation As IMVT-1402 And Earnings Outlook Draw Investor Focus

Simply Wall St.
·
May 19

Roivant Sciences price target raised to $29.50 from $29 at BofA

TIPRANKS
·
May 14